Skip to main content

Published locations for Ticagrelor gets FDA nod for DAPT in high-risk patients with CAD

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ticagrelor gets FDA nod for DAPT in high-risk patients with CAD

User login

  • Reset your password
  • /content/ticagrelor-gets-fda-nod-dapt-high-risk-patients-cad
  • /familypracticenews/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk
  • /hematologynews/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients
  • /internalmedicinenews/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk
  • /hospitalist/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients-cad
  • /hematology-oncology/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk
  • /ecardiologynews/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients
  • /cardiology/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients-cad
  • /internalmedicine/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients
  • /familymedicine/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients
  • /emergencymedicine/article/223177/cad-atherosclerosis/ticagrelor-gets-fda-nod-dapt-high-risk-patients